359 related articles for article (PubMed ID: 33615743)
1. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
Lu ZR; Laney VEA; Hall R; Ayat N
Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.
Gujrati M; Vaidya A; Lu ZR
Bioconjug Chem; 2016 Jan; 27(1):19-35. PubMed ID: 26629982
[TBL] [Abstract][Full Text] [Related]
3. Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation.
He S; Fan W; Wu N; Zhu J; Miao Y; Miao X; Li F; Zhang X; Gan Y
Nano Lett; 2018 Apr; 18(4):2411-2419. PubMed ID: 29561622
[TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release.
Gujrati M; Malamas A; Shin T; Jin E; Sun Y; Lu ZR
Mol Pharm; 2014 Aug; 11(8):2734-44. PubMed ID: 25020033
[TBL] [Abstract][Full Text] [Related]
6. Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.
Gujrati M; Vaidya AM; Mack M; Snyder D; Malamas A; Lu ZR
Adv Healthc Mater; 2016 Nov; 5(22):2882-2895. PubMed ID: 27723260
[TBL] [Abstract][Full Text] [Related]
7. Lipid-based nanoparticles in the systemic delivery of siRNA.
Lin Q; Chen J; Zhang Z; Zheng G
Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
[TBL] [Abstract][Full Text] [Related]
8. On the role of helper lipids in lipid nanoparticle formulations of siRNA.
Kulkarni JA; Witzigmann D; Leung J; Tam YYC; Cullis PR
Nanoscale; 2019 Nov; 11(45):21733-21739. PubMed ID: 31713568
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
11. Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy.
Saw PE; Yao H; Lin C; Tao W; Farokhzad OC; Xu X
Nano Lett; 2019 Sep; 19(9):5967-5974. PubMed ID: 31381852
[TBL] [Abstract][Full Text] [Related]
12. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
13. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
Mainini F; Eccles MR
Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
[TBL] [Abstract][Full Text] [Related]
14. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.
Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C
Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280
[TBL] [Abstract][Full Text] [Related]
15. Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.
Sarisozen C; Salzano G; Torchilin VP
Curr Pharm Biotechnol; 2016; 17(8):728-40. PubMed ID: 27033509
[TBL] [Abstract][Full Text] [Related]
16. A Review of pH-Responsive Organic-Inorganic Hybrid Nanoparticles for RNAi-Based Therapeutics.
Wang L; Yan Y
Macromol Biosci; 2021 Sep; 21(9):e2100183. PubMed ID: 34160896
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-siRNA: A potential cancer therapy?
Young SW; Stenzel M; Yang JL
Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in development of siRNA delivery vehicles for cancer therapy.
Kim HJ; Kim A; Miyata K; Kataoka K
Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
[TBL] [Abstract][Full Text] [Related]
19. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of RNAi nanomedicines.
Barros SA; Gollob JA
Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]